Parties d'ouvrages collectifs (1)
  1. 1. Robberecht, P., Vertongen, P., Langer, I., & Perret, J. (2003). Pituitary Adenylate Cyclase-Activating Polypeptide: Development of Selective Ligands for Pac1, Vpac1 and Vpac2 Receptors. In H. Vaudry & A. Arimura (Eds.), Pituitary Adenylate Cyclase-Activating Polypeptide: Development of Selective Ligands for Pac1, Vpac1 and Vpac2 Receptors, Vol. 20. Endocrine Updates (pp. 49-67). Springer US. doi:10.1007/978-1-4615-0243-2_3
    2.   Articles dans des revues avec comité de lecture (49)
  2. 1. Agostini, G., Leprovost, M., Jeandriens, J., Lefort, A., Libert, F., Sclafani, F., Langer, I., Hendlisz, A., & Garcia, M.-I. (2025). Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids. Frontiers in Cell and Developmental Biology. doi:10.3389/fcell.2025.1631116
  3. 2. Langer, I., Jeandriens, J., Couvineau, A., Sanmukh, S., & Latek, D. (2022). Signal Transduction by VIP and PACAP Receptors. Biomedicines, 10(2), 406. doi:10.3390/biomedicines10020406
  4. 3. Langer, I., & Latek, D. (2021). Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors. Frontiers in endocrinology, 12, 711906. doi:10.3389/fendo.2021.711906
  5. 4. Estienne, A., Mellouk, N., Bongrani, A., Plotton, I., Langer, I., Ramé, C., Petit, C., Guérif, F., Froment, P., & Dupont, J. (2021). Involvement of chemerin and CMKLR1 in the progesterone decrease by PCOS granulosa cells. Reproduction, 162(6), 427-436. doi:10.1530/REP-21-0265
  6. 5. Chraibi, S., Rosiere, R., De Prez, E., Gérard, P., Antoine, M.-H., Langer, I., Nortier, J., Remmelink, M., Amighi, K., & Wauthoz, N. (2021). Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer. Biomedicine & pharmacotherapy, 139, 111716. doi:10.1016/j.biopha.2021.111716
  7. 6. Chraibi, S., Rosiere, R., De Prez, E., Antoine, M.-H., Remmelink, M., Langer, I., Nortier, J., Amighi, K., & Wauthoz, N. (2021). Pulmonary and renal tolerance of cisplatin-based regimens combining intravenous and endotracheal routes for lung cancer treatment in mice. International journal of pharmaceutics, 599, 120425. doi:10.1016/j.ijpharm.2021.120425
  8. 7. Latek, D., Langer, I., Krzysko, K., & Charzynski, L. (2019). A Molecular Dynamics Study of Vasoactive Intestinal Peptide Receptor 1 and the Basis of Its Therapeutic Antagonism. International Journal of Molecular Sciences (CD-ROM), 20(18), 4348. doi:10.3390/ijms20184348
  9. 8. Peyrassol, X., Laeremans, T., Lahura, V., Debulpaep, M., El Hassan, H., Steyaert, J., Parmentier, M., & Langer, I. (2018). Development by genetic immunization of monovalent antibodies against human vasoactive intestinal peptide receptor 1 (VPAC1), new innovative, and versatile tools to study VPAC1 receptor function. Frontiers in endocrinology, 9(4), 153. doi:10.3389/fendo.2018.00153
  10. 9. Claes, K., Vandewalle, K., Laukens, B., Laeremans, T., Vosters, O., Langer, I., Parmentier, M., Steyaert, J., & Callewaert, N. (2016). Modular Integrated Secretory System Engineering in Pichia pastoris To Enhance G-Protein Coupled Receptor Expression. ACS synthetic biology. doi:10.1021/acssynbio.6b00032
  11. 10. Peyrassol, X., Laeremans, T., Gouwy, M., Lahura, V., Debulpaep, M., Van Damme, J., Steyaert, J., Parmentier, M., & Langer, I. (2016). Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor. The Journal of immunology, 196(6), 2893-2901. doi:10.4049/jimmunol.1500888
  12. 11. Rosiere, R., Van Woensel, M., Mathieu, V., Langer, I., Mathivet, T., Vermeersch, M., Amighi, K., & Wauthoz, N. (2016). Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy. International journal of pharmaceutics. doi:10.1016/j.ijpharm.2016.01.073
    13. << Précédent 1 2 3 4 5 6 7 8 Suivant >>